Skip to content

Multicenter Myocardial Viability Trial

An International, Multicenter Trial Assessing Myocardial Viability With Contrast - Enhanced Magnetic Resonance Imaging

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00661232
Enrollment
235
Registered
2008-04-18
Start date
2003-08-11
Completion date
2011-05-15
Last updated
2020-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

Myocardial Viability, Delayed Enhancement Magnetic Resonance Imaging, Functional Recovery

Brief summary

The purpose of this study is to test the hypothesis of whether contrast enhanced Magnetic Resonance Imaging can be used to predict improvement of the wall motion in regions of the heart with abnormal movement following bypass surgery or percutaneous angioplasty in various institutions across three continents.

Interventions

None listed

Sponsors

Medtronic - MITG
CollaboratorINDUSTRY
CHI St. Luke's Health, Texas
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Age: \> 21 years and \< 85 years * Sinus rhythm * Weight \< 120 kg * LVEF \> 30% * Wall motion abnormality on Echo. or LV-gram * Scheduled for revascularization - Angioplasty/Stent or CABG - within 30 days

Exclusion criteria

* Resting heart rate \> 100 bpm * Frequent atrial or ventricular ectopy * Severe aortic stenosis or HOCM * Unstable angina * Myocardial infarction within 14 days * Active congestive heart failure * Pregnancy * Known allergy to gadolinium * Contraindication to MRI

Design outcomes

Primary

MeasureTime frame
To examine whether the extent of irreversible myocardial injury as assessed by Delayed Enhancement Magnetic Resonance Imaging can predict the extent of functional recovery after revascularization in patients with chronic coronary artery disease (CAD).36 months

Countries

Belgium, Denmark, Greece, Thailand, United Kingdom, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026